Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 609-614

  Kaeser, Benoite ^a   Zandt, Hagen ^a   Bour, Fabrice ^c   Zwanziger, Elke ^a   Schmitt, Christophe ^a   Zhang, Xiaoping ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

^c Institut de Pharmacologie Clinique Roche   (France)

Author keywords

[No Author keywords available]

Indexed keywords

KETOCONAZOLE; RITONAVIR PLUS SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; RITONAVIR; SAQUINAVIR; YOUNG ADULT;

EID: 59749096917     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00769-08     Document Type: Article

References (5)

1. Baran, J., Jr., B. Muckatira, and R. Khatib. 2001. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand. J. Infect. Dis. 33:137-139.
2. Bjornsson, T. D., J. T. Callaghan, H. J. Einolf, V. Fischer, L. Gan, S. Grimm, J. Kao, S. P. King, G. Miwa, L. Ni, G. Kumar, J. McLeod, S. R. Obach, S. Roberts, A. Roe, A. Shah, F. Snikeris, J. T. Sullivan, D. Tweedie, J. M. Vega, J. Walsh, and S. A. Wrighton. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J. Clin. Pharmacol. 43:443-469.
3. Gerber, J. G. 2000. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin. Infect. Dis. 30(Suppl. 2):S123-S129.
4. Khaliq, Y., K. Gallicano, S. Venance, S. Kravick, and D. W. Cameron. 2000. Effect of ketoconazole on RTV and SQV concentrations in plasma and cerebrovascular fluid from patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 68:637-646.
5. U.S. Food and Drug Administration. 1999. Guidance for industry - in vivo drug metabolism/drug interaction studies: study design, data analysis, and recommendations for dosing and labeling. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Washington, DC. http://www.fda.gov/cder/guidance/index.htm.